Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

1 result

  • Active substance : ambrisentan
  • Topics : Population groups
Filter
Topic
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Drug therapy (1)
  • Diseases and conditions (1)
  • Plus ...
    • Respiratory tract diseases (1)
    • Plus ...
      • Pulmonary and pleural diseases (1)
    • Congenital, genetic and rare diseases (1)
    • Vascular diseases (1)
    • Plus ...
      • Hypertension (1)
  • Population groups (1)
  • Plus ...
    • Paediatrics (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Medicine (1)
Date
  • Last five years (1)
Langue
  • Français (1)
Substance active
  • ambrisentan (1)
More filter Other Filter Icon
Search Export

Drugs, devices and medical acts - 1 result

  • VOLIBRIS (ambrisentan), antihypertenseur

    Medicine - Posted on 23/11/2022
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
tf6FWABQ1NQ8RB5J